Research trends and hotspots of radioiodine-refractory thyroid cancer treatment in the twenty-first century: a bibliometric analysis
- PMID: 39499416
- PMCID: PMC11706862
- DOI: 10.1007/s12149-024-01998-2
Research trends and hotspots of radioiodine-refractory thyroid cancer treatment in the twenty-first century: a bibliometric analysis
Abstract
The treatment of radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) has made significant advancements in the twenty-first century. This study aimed to assess the current state of research and identify potential new directions by conducting a bibliometric analysis of scientific publications on RAIR-DTC treatment. Publications relevant to RAIR-DTC, published from January 1, 2000, to December 31, 2023, were retrieved from the Web of Science Core Collection. Bibliometric analyses of major keywords, authors, countries, institutions, publications, and journals were conducted using CiteSpace and VOSviewer. A total of 859 papers were included in the analysis. The results demonstrated a rising trend in the number of publications over time. The United States was identified as the leading contributor in terms of publication output, citations, and international collaborations. Gustave Roussy emerged as the top organization in publication productivity, while the journal Thyroid had the highest number of related publications. The research on RAIR treatment was categorized into three key hotspots: clinical trials of targeted therapies, novel therapeutic strategies, and debates surrounding the RAIR-DTC management. RAIR-DTC research is expanding from the clinical trial phase of tyrosine kinase inhibitor monotherapy to a more complex combination therapy strategy, in particular, the synergistic effect of immune checkpoint inhibitors and other therapeutic agents, requiring more high-quality prospective studies to validate the clinical benefits. Moreover, the timely identification of RAIR-DTC patients holds the potential to enable early disease intervention, constituting a pivotal novel research direction in the future.
Keywords: Bibliometric analysis; Citespace; Radioiodine-refractory; Thyroid cancer; Treatment; VOSviewer.
© 2024. The Author(s).
Conflict of interest statement
Declarations. Conflict of interest: The authors declare that they have no potential conflict of interest.
Figures







Similar articles
-
Global research landscape and trends of papillary thyroid cancer therapy: a bibliometric analysis.Front Endocrinol (Lausanne). 2023 Sep 19;14:1252389. doi: 10.3389/fendo.2023.1252389. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37795362 Free PMC article.
-
Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: A systematic review and meta-analysis.Clin Endocrinol (Oxf). 2024 Apr;100(4):379-388. doi: 10.1111/cen.15027. Epub 2024 Feb 13. Clin Endocrinol (Oxf). 2024. PMID: 38351437
-
Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead.Front Endocrinol (Lausanne). 2022 Jul 12;13:924841. doi: 10.3389/fendo.2022.924841. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35903277 Free PMC article. Review.
-
Radioiodine-refractory differentiated thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine resistance.Drug Resist Updat. 2024 Jan;72:101013. doi: 10.1016/j.drup.2023.101013. Epub 2023 Oct 22. Drug Resist Updat. 2024. PMID: 38041877 Review.
-
TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer.Sci Rep. 2024 Oct 10;14(1):23719. doi: 10.1038/s41598-024-75087-9. Sci Rep. 2024. PMID: 39390090 Free PMC article.
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. - PubMed
-
- Viola D, Valerio L, Molinaro E, Agate L, Bottici V, Biagini A, et al. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. Endocr Relat Cancer. 2016;23:R185-205. - PubMed
-
- Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133. - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical